Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) Short Interest Update

Posted by Scott Moore on Mar 27th, 2026

Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR – Get Free Report) saw a large drop in short interest in the month of March. As of March 13th, there was short interest totaling 622 shares, a drop of 43.3% from the February 26th total of 1,097 shares. Based on an average trading volume of 1,322 shares, the short-interest ratio is currently 0.5 days. Approximately 0.4% of the shares of the company are sold short.

Amplify Weight Loss Drug & Treatment ETF Price Performance

Shares of Amplify Weight Loss Drug & Treatment ETF stock remained flat at $23.67 on Friday. 71 shares of the stock were exchanged, compared to its average volume of 2,674. Amplify Weight Loss Drug & Treatment ETF has a twelve month low of $18.56 and a twelve month high of $27.28. The stock’s fifty day simple moving average is $25.52 and its two-hundred day simple moving average is $24.88. The firm has a market capitalization of $3.55 million, a price-to-earnings ratio of 24.31 and a beta of 0.61.

Amplify Weight Loss Drug & Treatment ETF Dividend Announcement

The firm also recently announced an annual dividend, which was paid on Wednesday, December 31st. Stockholders of record on Tuesday, December 30th were paid a dividend of $0.4132 per share. This represents a dividend yield of 162.0%. The ex-dividend date of this dividend was Tuesday, December 30th.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Amplify Weight Loss Drug & Treatment ETF stock. Jane Street Group LLC lifted its stake in shares of Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR – Free Report) by 5.1% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 24,891 shares of the company’s stock after purchasing an additional 1,215 shares during the quarter. Jane Street Group LLC owned about 19.15% of Amplify Weight Loss Drug & Treatment ETF worth $536,000 at the end of the most recent quarter.

Amplify Weight Loss Drug & Treatment ETF Company Profile

(Get Free Report)

The Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.